Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

Inclusion Criteria: * Written informed consent * Newly diagnosed multiple myeloma * Maximum of one prior systemic therapy (2 cycles) * Presence of CRAB criteria * Measurable disease parameters * Left ventricular ejection fraction at least 55% * DLCO of at least 60% * Adequate bone marrow function * Use of adequate contraception for female subjects with childbearing potential and all male subjects * Eligible for autologous and allogeneic stem cell transplantation * Bone marrow baseline sample evaluable for interphase cytogenetics Exclusion Criteria: * Any serious medical conditions preventing the subject from written informed consent * Progressive disease (PD) to any initial treatment * Pregnant or lactating females * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data * Use of any other experimental drug or therapy within 28 days of baseline * Preexisting neuropathy of ≥ grade 2 severity * Known hypersensitivity to thalidomide * Any prior use of lenalidomide * Positive for HIV or infectious hepatitis, type A, B or C after serologic testing * Serum creatinine despite induction therapy ≥ 2.0 mg/dL